Frontiers in drug delivery最新文献

筛选
英文 中文
Poor-tasting pediatric medicines: part 2. Exploring caregiver and healthcare provider values and preferences for a novel taste-blocker product to improve acceptability. 味道差的儿科药物:第2部分。探索护理人员和医疗保健提供者的价值观和偏好的一种新的味道阻断产品,以提高可接受性。
Frontiers in drug delivery Pub Date : 2025-04-22 eCollection Date: 2025-01-01 DOI: 10.3389/fddev.2025.1555522
Moushira El-Sahn, Rose Elliott, Mona El-Sahn, Izaak Lucas, Karen Kong, Jennifer Walsh, Jeff Lucas
{"title":"Poor-tasting pediatric medicines: part 2. Exploring caregiver and healthcare provider values and preferences for a novel taste-blocker product to improve acceptability.","authors":"Moushira El-Sahn, Rose Elliott, Mona El-Sahn, Izaak Lucas, Karen Kong, Jennifer Walsh, Jeff Lucas","doi":"10.3389/fddev.2025.1555522","DOIUrl":"10.3389/fddev.2025.1555522","url":null,"abstract":"<p><strong>Introduction: </strong>Improving the palatability of bitter-tasting medication for pediatric populations has long presented a challenge. Taste blockers are being researched as a potential solution; however, end-user perspectives and needs related to this concept have not been explored. The objectives of this research were 1) to understand current experiences of administering bitter-tasting medication; 2) the evaluation of a consumer-targeted product profile (CTPP) for a taste blocker including attributes such as form and duration of action; and 3) whether there is a need to support improved acceptability and adherence with a taste blocker taken before the bitter-tasting medication.</p><p><strong>Methods: </strong>Our study consisted of simultaneous qualitative and quantitative phases, involving caregivers and healthcare providers with experience administering medications to children aged 2-17 years. Qualitative research was conducted with 120 caregivers and 92 healthcare providers using a range of methods. Focus groups (FGs) were conducted in Kenya, Nigeria and Zimbabwe (grouped as Sub-Saharan Africa (SSA) but not intended to be representative of the region as a whole) with caregivers of children who had taken medication for HIV, TB, pneumonia, or malaria (including for seasonal prevention) within the past 6 months. Telephone in-depth interviews (TDIs) were conducted with caregivers of children with chronic illnesses in the United States. Face-to-face in-depth interviews (IDIs) and TDIs were conducted with healthcare providers. The quantitative part of the study was conducted with n = 1,815 caregivers and n = 859 healthcare providers using face-to-face computer-assisted interviews (CAPI) in SSA, and <i>via</i> online panel research in the United States A CTPP was used as the stimulus for discussion. Participants were asked about their experiences in giving bitter-tasting medication to their children or patients, their perceptions of and willingness to try a taste blocker, and their preferences for specific product attributes.</p><p><strong>Results: </strong>Participants described how bitter-tasting medications create challenges in multiple areas: for caregivers, children, their daily life and routines, healthcare providers, and children's perceptions of healthcare. In SSA, 28.9% of caregivers reported that their children <i>always</i> or <i>regularly</i> refused medication due to bitter taste, while 57.9% reported this in the United States. Another 36.2% and 29.1% respectively experienced this <i>sometimes</i> or <i>occasionally</i>. Over 80% of providers in all countries stated that bitter taste impacts adherence to both long and short-term medication. The preferred attributes of the taste blocker were a sweetened and flavored lollipop form with a maximum total duration of up to approximately 1h, and with a total taste block achieved as soon as possible. Overall, responses to the concept of the taste blocker were positive from caregiv","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"5 ","pages":"1555522"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Grand challenges in oral drug delivery. 口服给药的巨大挑战。
Frontiers in drug delivery Pub Date : 2025-02-19 eCollection Date: 2025-01-01 DOI: 10.3389/fddev.2025.1571982
Driton Vllasaliu
{"title":"Grand challenges in oral drug delivery.","authors":"Driton Vllasaliu","doi":"10.3389/fddev.2025.1571982","DOIUrl":"10.3389/fddev.2025.1571982","url":null,"abstract":"","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"5 ","pages":"1571982"},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum: Preliminary results on novel adjuvant combinations suggest enhancement immunogenicity of whole inactivated pandemic influenza vaccines. 勘误:新型佐剂组合的初步结果表明,全灭活大流行性流感疫苗的免疫原性增强。
Frontiers in drug delivery Pub Date : 2024-12-16 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1519969
Allegra Peletta, Aurélie Marmy, Samo Guzelj, Alcidia Ramos Barros, Žiga Jakopin, Gerrit Borchard
{"title":"Corrigendum: Preliminary results on novel adjuvant combinations suggest enhancement immunogenicity of whole inactivated pandemic influenza vaccines.","authors":"Allegra Peletta, Aurélie Marmy, Samo Guzelj, Alcidia Ramos Barros, Žiga Jakopin, Gerrit Borchard","doi":"10.3389/fddev.2024.1519969","DOIUrl":"10.3389/fddev.2024.1519969","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fddev.2024.1382266.].</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1519969"},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: 3D printing in pharmaceuticals and medical applications. 社论:3D打印在制药和医疗应用。
Frontiers in drug delivery Pub Date : 2024-11-26 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1527225
Italo Rodrigo Calori, Dimitrios A Lamprou
{"title":"Editorial: 3D printing in pharmaceuticals and medical applications.","authors":"Italo Rodrigo Calori, Dimitrios A Lamprou","doi":"10.3389/fddev.2024.1527225","DOIUrl":"10.3389/fddev.2024.1527225","url":null,"abstract":"","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1527225"},"PeriodicalIF":0.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting aerosol delivery to regions of nasal-associated lymphoid tissue (NALT) in three dimensional models of human intranasal airways using the BiVax intranasal atomizer. 在人鼻内气道三维模型中,使用BiVax鼻内雾化器将气溶胶输送到鼻相关淋巴组织(NALT)区域。
Frontiers in drug delivery Pub Date : 2024-11-11 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1456538
Beth L Laube, Jana Kesavan, Gonçalo Farias, Nektaria Karavas, Mathilde Blondel, Julie Suman
{"title":"Targeting aerosol delivery to regions of nasal-associated lymphoid tissue (NALT) in three dimensional models of human intranasal airways using the BiVax intranasal atomizer.","authors":"Beth L Laube, Jana Kesavan, Gonçalo Farias, Nektaria Karavas, Mathilde Blondel, Julie Suman","doi":"10.3389/fddev.2024.1456538","DOIUrl":"10.3389/fddev.2024.1456538","url":null,"abstract":"<p><strong>Introduction: </strong>Well-organized nasal-associated lymphoid tissue (NALT) has been identified in the pharyngeal and tubal tonsils of both adults and children, and diffuse NALT has been identified in the superior, middle and inferior turbinate regions of children. However, it is not clear how to target these NALT sites with aerosolized vaccines. We explored whether head position and/or angle and distance of device insertion could be used to target fluorescein aerosol to NALT sites in three-dimensional printed models of the intranasal airways of an 18- and a 5-year-old (yo).</p><p><strong>Methods: </strong>Three head positions (upright [Up], tilted back 45° [45] and supine [Su]), two angles of insertion (30° and 45°) and two distances of insertion (6 mm and 9 mm) were tested. Fluorescein aerosol was generated by an Aptar Pharma BiVax 200 µL intranasal atomizer. Percent fluorescein deposition was quantified in the anterior nose, the upper horizontal third of the model (superior turbinate region), middle third (middle turbinate), lower third (inferior turbinate and nasopharynx combined) and exit filter.</p><p><strong>Results: </strong>Mean percent deposition in both models was <0.5% in the upper third and on the exit filter for all test conditions. A multivariate analysis showed that deposition in either model was unaffected by the angles of insertion and distances of insertion. However, middle third deposition was significantly higher in the 5-yo than in the 18-yo (<i>p</i> = 0.01) and anterior nose deposition was higher in the 18-yo than in the 5-yo (<i>p</i> < 0.01). When data from both models were combined, middle third deposition was highest in the supine position with Up < 45 < Su (<i>p</i> < 0.01) and lower third deposition was highest in the upright position with Up > 45 > Su (<i>p</i> = 0.03).</p><p><strong>Discussion: </strong>These results suggest that, in individuals with similar nasal airway dimensions as our models: 1) supine and upright head positions might be used to target delivery of aerosolized vaccines generated by the BiVax intranasal atomizer to NALT sites in the middle turbinate and the inferior turbinate and nasopharynx combined, respectively; 2) delivery to the middle turbinate may be higher in children ≤5-yo; and 3) deposition in the anterior nose may be higher in adults, for all head positions. <i>In vivo</i> tests are needed to confirm these findings.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1456538"},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery. 治疗糖尿病和肥胖症的胰高血糖素样肽-1受体激动剂:口服给药的优势。
Frontiers in drug delivery Pub Date : 2024-11-06 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1456654
R R C New, M Bogus, G N Travers, U Hahn, A Vaiceliunaite, M Burnet, J H Wang, H Wen
{"title":"Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery.","authors":"R R C New, M Bogus, G N Travers, U Hahn, A Vaiceliunaite, M Burnet, J H Wang, H Wen","doi":"10.3389/fddev.2024.1456654","DOIUrl":"10.3389/fddev.2024.1456654","url":null,"abstract":"<p><p>GLP-1 receptor agonists ((GLP-1 RAs) are currently receiving a lot of attention because of their impact in diabetes, weight loss and other areas. While GLP-1 RAs in injectable form are highly efficacious, further work is required to develop oral versions which can deliver these peptides efficiently without requiring use of excessively high doses. This paper describes the ability of an oral peptide delivery formulation, Axcess™, to enhance uptake of GLP-1 receptor agonists via the intestine, resulting in changes in insulin and glucose blood levels indicative of biopotencies of 9% for exendin-4 and 14.8% for semaglutide in preclinical models. The route of delivery suggests that the peptides will be able to interact with the GLP-1 receptors on the vagal afferents of the intestine, as is the case for native GLP-1 in healthy individuals. GLP-1 receptor agonists administered via this route will be a valuable addition to the therapeutic modalities available for treatment of diabetes and obesity.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1456654"},"PeriodicalIF":0.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Women in CNS drug delivery: 2022-2024. 社论:女性参与中枢神经系统给药:2022-2024。
Frontiers in drug delivery Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1400937
Szilvia Veszelka, Malgorzata Burek, Sarah Ann Thomas
{"title":"Editorial: Women in CNS drug delivery: 2022-2024.","authors":"Szilvia Veszelka, Malgorzata Burek, Sarah Ann Thomas","doi":"10.3389/fddev.2024.1400937","DOIUrl":"10.3389/fddev.2024.1400937","url":null,"abstract":"","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1400937"},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Electrospun patches to deliver combination drug therapy for fungal infections. 静电纺丝贴片为真菌感染提供联合药物治疗。
Frontiers in drug delivery Pub Date : 2024-09-16 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1458009
Karolina Dziemidowicz, Mark Meszarik, Jacopo Piovesan, Mazna A Almatroudi, Gareth R Williams, Sudaxshina Murdan
{"title":"Electrospun patches to deliver combination drug therapy for fungal infections.","authors":"Karolina Dziemidowicz, Mark Meszarik, Jacopo Piovesan, Mazna A Almatroudi, Gareth R Williams, Sudaxshina Murdan","doi":"10.3389/fddev.2024.1458009","DOIUrl":"10.3389/fddev.2024.1458009","url":null,"abstract":"<p><p>Fungal infections, though affecting healthcare globally, receive insufficient attention in clinical and academic settings. Invasive fungal infections, particularly caused by combat wounds, have been identified as a critical threat by the US Department of Defense. Monotherapy with traditional antifungals is often insufficient, and so combination therapies are explored to enhance treatment efficacy. However, systemic combination treatments can result in severe adverse effects, suggesting the need for localised delivery systems, such as drug-loaded electrospun patches, to administer antifungals directly to the infection site. This proof-of-concept study hypothesised that dual amorolfine and terbinafine therapy slowly releasing from electrospun patches would be an effective way of eradicating <i>Candida albicans</i> when the patch was applied directly to the fungal colony. The feasibility of creating electrospun materials loaded with amorolfine and terbinafine for combination antifungal therapy was investigated. Electrospinning was used to fabricate polycaprolactone (PCL) patches with varying drug loadings (2.5%, 5%, and 10% w/w) of amorolfine and terbinafine either individually or in combination. The incorporation of both drugs in the fibres was confirmed, with the drugs predominantly in an amorphous state. Results showed that combination therapy patches had a significantly greater and prolonged antifungal effect compared to monotherapy patches, with larger zones of inhibition and sustained efficacy over at least 7 days. This study therefore demonstrates that PCL-based electrospun patches containing amorolfine and terbinafine provide superior antifungal activity against <i>C. albicans</i> compared to monotherapy patches. This approach could lower required drug doses, reducing adverse effects, and enhance patient compliance due to prolonged drug release, leading to more effective antifungal therapy.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1458009"},"PeriodicalIF":0.0,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A selective review of inhibitors of protein kinase C gamma: a neuroplasticity-related common pathway for psychiatric illness. 蛋白激酶C γ抑制剂的选择性回顾:精神疾病的神经可塑性相关的共同途径。
Frontiers in drug delivery Pub Date : 2024-09-13 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1364037
Marco Grados, Mona Salehi, Aida Lotfi, Sagar Dua, Isabella Xie
{"title":"A selective review of inhibitors of protein kinase C gamma: a neuroplasticity-related common pathway for psychiatric illness.","authors":"Marco Grados, Mona Salehi, Aida Lotfi, Sagar Dua, Isabella Xie","doi":"10.3389/fddev.2024.1364037","DOIUrl":"10.3389/fddev.2024.1364037","url":null,"abstract":"<p><p>Psychotropics are currently developed and marketed with a limited understanding of their mechanism of action. The notion that protein kinase C (PKC) activity is highly relevant to learning and memory function stems from experiments in the 1980s, which associated protein kinase alpha (pka) and pkc to animal models of associative learning, opening an area of exploration for psychotropic development. The PKC family consists of several isoforms, including PKC alpha, beta1, beta1, gamma, delta and epsilon among others. In particular, PKC gamma (PRKCG) is highly brain-expressed and is singled out as a candidate for modulation in psychiatric illness. With hundreds of identified substrates, PRKCG affects multiple pathways relevant for regulation of neuronal health. In this review, converging lines of evidence are presented in the context of psychotropic drug action, which point to downregulation of PKC activity as a potential common mechanism across several psychiatric disorders. Using this mechanism through more targeted psychotropic action may then be used to develop agents that further ameliorate psychiatric symptom expression. Psychotropics including fluoxetine, tricyclics, lithium, valproate, ketamine and others are explored in relation to their effect of PKC, finding that across all drugs examined, a downregulation with chronic-but not acute-use constitutes their putative effect in ameliorating symptoms. This effect is compounded by findings that suggest that PKCs, and PRKCG in particular, promote neuroplastic effects by their downregulation. This effect is in contrast to PKC activators, which have been used in neurodegenerative disorders such as Alzheimer's disease. Cross-disorder mechanisms need to continue to be explored in neuropsychiatric illness and targeted treatments developed in turn to address treatment-resistant conditions.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1364037"},"PeriodicalIF":0.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preclinical evaluation of a novel antibiotic-eluting BioEnvelope for CIED infection prevention. 新型抗生素洗脱生物包膜预防CIED感染的临床前评价。
Frontiers in drug delivery Pub Date : 2024-09-10 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1441956
Zerelda Esquer Garrigos, John N Catanzaro, Daniel Deegan, Ji Zhang, M Rizwan Sohail
{"title":"Preclinical evaluation of a novel antibiotic-eluting BioEnvelope for CIED infection prevention.","authors":"Zerelda Esquer Garrigos, John N Catanzaro, Daniel Deegan, Ji Zhang, M Rizwan Sohail","doi":"10.3389/fddev.2024.1441956","DOIUrl":"10.3389/fddev.2024.1441956","url":null,"abstract":"<p><p>The risk of infection remains a significant concern with cardiovascular implantable electronic devices, necessitating the development of new strategies. This study explores the efficacy of a novel antibiotic-eluting biologic envelope designed to mitigate infection risk through localized antibiotic delivery while preserving the regenerative properties of biological matrix. Antibiotics, rifampin and minocycline, are released through polymer discs, ensuring extended drug release. Utilizing an established model of infection in a New Zealand White rabbit, the study assessed performance against Gram-positive bacterial strains, including common pathogens such as <i>Staphylococcus aureus</i> and <i>S. epidermidis</i> associated with CIED infections, and Gram-negative bacterial strains. Results demonstrated strong antibacterial activity, achieving complete eradication of bacterial colonies and greater than 6-log reductions in colonization for all strains. Pharmacokinetic analysis revealed sustained local antibiotic concentrations at the implantation site for up to 14 days, with minimal systemic exposure, demonstrating the advantages of localized drug delivery. Health outcomes in the antibiotic bioenvelope group were significantly improved, with no signs of infection or abnormal body temperatures, in contrast to the control group. Macroscopic examinations post-necropsy confirmed the absence of infection at the implantation sites of animals receiving the antibiotic bioenvelope. The combination of localized antibiotic delivery in a regenerative matrix positions the antibiotic bioenvelope as a promising solution for preventing CIED-related infections.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1441956"},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信